FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2549271830> ?p ?o ?g. }

• W2549271830 abstract "Inhibitors of checkpoint kinases, such as ATR, Chk1 or Wee1, in combination with cytotoxic agents could enhance therapeutic efficacy compared to monotherapy, and these combination approaches are currently being extensively explored. The presence of replicative stress or deregulated S-phase in cancer has been recognized as a rationale for the use of ATR and Chk1 inhibitors with chemotherapy and efforts are underway to define genetic determinants that sensitize cancer cells to ATR inhibition. Pharmacodynamic (PD) biomarkers of drug activity are valuable tools in clinical trials using targeted agents to determine whether each investigational agent is acting upon its intended target, the expected intracellular signaling pathways are modulated, and the dosage regimen and sequencing are optimal. In addition, investigations of the potential effects of cell cycle distribution within the tumor (in animal models) on drug efficacy may point to alternative dosing regimens. The first clinical trials evaluating inhibitors of the ataxia telangiectasia and Rad3-related kinase (ATR) in combination with cytotoxic agents are enrolling patients. The current method for quantifying ATR inhibition used in preclinical in vitro and in vivo models is via indirect measurement of downstream effector proteins, such as phosphorylated Chk1, rather than measurement of direct target engagement. We propose that an immunofluorescence microscopy assay of ATR autophosphorylation status as a biomarker of DNA damage activation combined with measurement of the downstream effector proteins will reveal more specific information about target engagement and intended PD effect than would be obtained from a single-biomarker assay. Here we propose that the measurement of ATR pT1989, Chk1 pS345 and γH2AX by validated quantitative immunofluorescence assays will be useful in PD evaluation of tumor responses in clinical trials as a biomarker for ATR pathway activation or inhibition. In addition, evaluation of the variability of expression of activated ATR in tumor models of different histologies may provide valuable insight into tumor types likely to be sensitive to ATR inhibitors. Citation Format: Deborah Wilsker, Allison M. Marrero, Angie Dull, Thomas D. Pfister, Scott M. Lawrence, John Carter, Michelle Gottholm-Ahalt, Melinda Hollingshead, James Doroshow, Ralph E. Parchment, Robert J. Kinders. Ataxia-telangiectasia and Rad3-related (ATR) phosphorylation as a pharmacodynamic biomarker of ATR activation in solid tumor tissue models. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Cancer Cell Cycle - Tumor Progression and Therapeutic Response; Feb 28-Mar 2, 2016; Orlando, FL. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(11_Suppl):Abstract nr B24." @default.
• W2549271830 created "2016-11-30" @default.
• W2549271830 creator A5007831491 @default.
• W2549271830 creator A5014611111 @default.
• W2549271830 creator A5020492035 @default.
• W2549271830 creator A5032932491 @default.
• W2549271830 creator A5041200743 @default.
• W2549271830 creator A5057382599 @default.
• W2549271830 creator A5064476636 @default.
• W2549271830 creator A5066734696 @default.
• W2549271830 creator A5071764105 @default.
• W2549271830 creator A5080778766 @default.
• W2549271830 creator A5090468019 @default.
• W2549271830 date "2016-11-01" @default.
• W2549271830 modified "2023-10-14" @default.
• W2549271830 title "Abstract B24: Ataxia-telangiectasia and Rad3-related (ATR) phosphorylation as a pharmacodynamic biomarker of ATR activation in solid tumor tissue models" @default.
• W2549271830 doi "https://doi.org/10.1158/1557-3125.cellcycle16-b24" @default.
• W2549271830 hasPublicationYear "2016" @default.
• W2549271830 type Work @default.
• W2549271830 sameAs 2549271830 @default.
• W2549271830 citedByCount "1" @default.
• W2549271830 countsByYear W25492718302021 @default.
• W2549271830 crossrefType "proceedings-article" @default.
• W2549271830 hasAuthorship W2549271830A5007831491 @default.
• W2549271830 hasAuthorship W2549271830A5014611111 @default.
• W2549271830 hasAuthorship W2549271830A5020492035 @default.
• W2549271830 hasAuthorship W2549271830A5032932491 @default.
• W2549271830 hasAuthorship W2549271830A5041200743 @default.
• W2549271830 hasAuthorship W2549271830A5057382599 @default.
• W2549271830 hasAuthorship W2549271830A5064476636 @default.
• W2549271830 hasAuthorship W2549271830A5066734696 @default.
• W2549271830 hasAuthorship W2549271830A5071764105 @default.
• W2549271830 hasAuthorship W2549271830A5080778766 @default.
• W2549271830 hasAuthorship W2549271830A5090468019 @default.
• W2549271830 hasConcept C121608353 @default.
• W2549271830 hasConcept C126322002 @default.
• W2549271830 hasConcept C143425029 @default.
• W2549271830 hasConcept C2781197716 @default.
• W2549271830 hasConcept C502942594 @default.
• W2549271830 hasConcept C552990157 @default.
• W2549271830 hasConcept C55493867 @default.
• W2549271830 hasConcept C71924100 @default.
• W2549271830 hasConcept C86803240 @default.
• W2549271830 hasConcept C98274493 @default.
• W2549271830 hasConceptScore W2549271830C121608353 @default.
• W2549271830 hasConceptScore W2549271830C126322002 @default.
• W2549271830 hasConceptScore W2549271830C143425029 @default.
• W2549271830 hasConceptScore W2549271830C2781197716 @default.
• W2549271830 hasConceptScore W2549271830C502942594 @default.
• W2549271830 hasConceptScore W2549271830C552990157 @default.
• W2549271830 hasConceptScore W2549271830C55493867 @default.
• W2549271830 hasConceptScore W2549271830C71924100 @default.
• W2549271830 hasConceptScore W2549271830C86803240 @default.
• W2549271830 hasConceptScore W2549271830C98274493 @default.
• W2549271830 hasLocation W25492718301 @default.
• W2549271830 hasOpenAccess W2549271830 @default.
• W2549271830 hasPrimaryLocation W25492718301 @default.
• W2549271830 hasRelatedWork W10037315 @default.
• W2549271830 hasRelatedWork W13548206 @default.
• W2549271830 hasRelatedWork W19037765 @default.
• W2549271830 hasRelatedWork W20034969 @default.
• W2549271830 hasRelatedWork W22424186 @default.
• W2549271830 hasRelatedWork W22446976 @default.
• W2549271830 hasRelatedWork W31034207 @default.
• W2549271830 hasRelatedWork W35045942 @default.
• W2549271830 hasRelatedWork W36399790 @default.
• W2549271830 hasRelatedWork W37091630 @default.
• W2549271830 isParatext "false" @default.
• W2549271830 isRetracted "false" @default.
• W2549271830 magId "2549271830" @default.
• W2549271830 workType "article" @default.